Abstract
The effect of ranitidine in preventing mucosal damage caused by nonsteroidal antiinflammatory drugs (NSAIDs) was evaluated for eight weeks in a prospective study of 144 patients requiring NSAIDs. Patients with normal endoscopic findings were randomly assigned to receive either ranitidine 150 mg twice daily or placebo for eight weeks, along with either ibuprofen, indomethacin, naproxen, sulindac, or piroxicam. Duodenal damage was significantly less in the ranitidine group compared with the placebo group by weeks 4 and 8 (P≤0.01). Duodenal ulcers did not develop in any patients on ranitidine (0/57) compared with 4/49 patients (8%) on placebo (P=0.02). No significant difference was found between treatment groups with respect to gastric damage; 6/60 (10%) in the ranitidine group compared with 6/50 (12%) in the placebo group developed gastric ulcers. These findings suggest that acid suppression is of greater importance for mucosal protection in the duodenum than in the stomach, where other defense mechanisms may be operative. While ranitidine is an effective prophylaxis for NSAID-induced damage in the duodenum, further studies are needed to define specific risk groups and to assess the potential usefulness of more complete acid suppression in preventing gastric mucosal damage.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lanza F, Royer G, Nelson R, et al: A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 75:17–21, 1981
Lanza FL, Royer GL, Nelson RS, et al: The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers. Dig Dis Sci 24(11):823–828, 1979
Ivey KJ, Paone DB, Krause WJ: Acute effect of systemic aspirin on gastric mucosae in man. Dig Dis Sci 25:97–99, 1980
Pemberton RE, Strand LJ: A review of upper gastrointestinal effects of the newer nonsteroidal antiinflammatory agents. Dig Dis Sci 24(l):53–64, 1979
Somerville K, Faulkner G, Langman M: Nonsteroidal antiinflammatory drugs and bleeding peptic ulcer. Lancet 1:462–464, 1986
Carson JL, Strom BL, Soper KA, West SI, Morse ML: The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intrn Med 147:85–88, 1987
Silvoso GR, Ivey KJ, Butt JH, Lockard OO, Holt S: Incidence of gastric lesions in patients with rheumatic diseases on chronic antiinflammatory therapy. Gastroenterology 74:1095, 1978
Collier D, Pain J: Non-steroidal anti-inflammatory drugs and peptic ulcer perforation. Gut 26:359–363, 1985
Caldwell JR, Roth SH, Wu WC, et al: Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage. Am J Med 83(Suppl 3B):74–82, 1987
Tesler MA, Lim ES: Protection of gastric mucosa by sucralfate from aspirin-induced erosions. J Clin Gastroenterol 3(suppl 2):175–179, 1981
Lanza F, Peace K, Gustitus L, Rack MF, Dickson B: A blinded endoscopic comparative study of misoprostol versus sucralfate and placeo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 83(2):143–146, 1988
Lanza F: A double-blind study of prophylactic effect of misoprostol on lesions of gastric and duodenal mucosa induced by oral administration of tolmetin in healthy subjects. Dig Dis Sci 31(2):131S-136S, 1986
Berkowitz JM, Rogenes PR, Sharp JT, Warner CW: Ranitidine protects against gastroduodenal mucosal damage associated with chronic aspirin therapy. Arch Intern Med 147:2137–2139, 1987
Hawkey CJ, Somerville KW, Marshall S: Prophylaxis of aspirin-induced gastric mucosal bleeding with ranitidine. Aliment Pharmacol Ther 2:245–252, 1988
Roth SH, Bennett RE, Mitchell CS, et al: Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy: Double-blind long-term evaluation. Arch Intern Med 147:1798–1801, 1987
Duggan JM, Dobson AJ, Johnson H, Fahey P: Peptic ulcer and non-steroidal anti-inflammatory agents. Gut 27:929–933, 1986
Roth SH, Bennett RE: Nonsteroidal anti-inflammatory drug gastropathy: Recognition and response. Arch Intern Med 147:2093–2100, 1987
Lockard OO, Ivey KJ, Butt JH, et al: The prevalence of duodenal lesions in patients with rheumatic diseases on chronic aspirin therapy. Gastrointest Endosc 26(l):5–7, 1980
Larkai, EN, Smith JL, Lidsky MD, Graham DY: Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal antiinflammatory drug use. Am J Gastroenterol 82(11):1153–1158, 1987
Ehsanullah RSB, Page MC, Tildesley G, Wood JR: Nonsteroidal anti-inflammatory drug-induced gastroduodenal damage: Prophylactic effect of inhibition of gastric acid secretion. Br Med J 297 (6655):1017–1021, 1988
Caruso I, Bianchi Porro G: Gastroscopic evaluation of anti-inflammatory agents. Br Med J 280:75–78, 1980
Clinch D, Banerjee AK, Levy DM, Ostick G, Faragher EB: Non-steroidal anti-inflammatory drugs and peptic ulceration. J R Coll Physicians London 21:183–187, 1987
Morris AD, Holt SD, Silvoso GR, et al: Effect of antiinflammatory drug administration in patients with rheumatoid arthritis: An endoscopic assessment. Scand J Gastroenterol 67:131–135, 1981
Mellem H, Stave R, Myren J, et al: Symptoms in patients with peptic ulcer and hematemesis and/or melena related to the use of non-steroid anti-inflammatory drugs. Scand J Gastroenterol 20:1246–1248, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Robinson, M.G., Griffin, J.W., Bowers, J. et al. Effect of ranitidine gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs. Digest Dis Sci 34, 424–428 (1989). https://doi.org/10.1007/BF01536266
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01536266